Skip to main content

Table 1 The characteristics of the DCIS, IDC-no-relapse and IDC-with-relapse patients included in the study

From: Inflammatory mediators in breast cancer: Coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition

Patient characteristics DCIS IDC -
No Relapse
IDC -
With Relapse
   n = 30 (%) n = 23 (%) n = 35 (%)
Menopause
status
Pre-menopause 3 (10.0%) 0 (0.0%) 7 (20.0%)
  Menopause 7 (23.3%) 0 (0.0%) 0 (0.0%)
  Post-menopause 8 (26.7%) 0 (0.0%) 25 (71.4%)
  Unknown 12 (40.0%) 23 (100.0%) 3 (8.6%)
Node status N0 30 (100.0%) 14 (60.9%) 17 (48.6%)
  N1 0 (0.0%) 4 (17.4%) 14 (40.0%)
  N2 0 (0.0%) 1 (4.4%) 0 (0.0%)
  Unknown 0 (0.0%) 4 (17.4%) 4 (11.4%)
Tumor T0 26 (86.7%) 0 (0.0%) 1 (2.9%)
  T1 0 (0.0%) 2 (8.7%) 14 (40.0%)
  T≥2 0 (0.0%) 19 (82.6%) 17 (48.6%)
  Unknown 4 (13.3%) 2 (8.7%) 3 (8.5%)
Grade 1 5 (16.7%) 6 (26.1%) 5 (14.3%)
  2 12 (40.0%) 9 (39.1%) 10 (28.6%)
  3 6 (20.0%) 5 (21.7%) 7 (20.0%)
  Unknown 7 (23.3%) 3 (13.1%) 13 (37.1%)
Radiotherapy Yes 19 (63.4%) 17 (73.9%) 28 (80.0%)
  No 10 (33.3%) 5 (21.7%) 5 (14.3%)
  Unknown 1 (3.3%) 1 (4.4%) 2 (5.7%)
Chemotherapy Yes 0 (0.0%) 17 (73.9%) 15 (42.9%)
  No 18 (60.0%) 5 (21.7%) 17 (48.6%)
  Unknown 12 (40.0%) 1 (4.3%) 3 (8.5%)
Her2-neu Yes 3 (10.0%) 1 (4.3%) 6 (17.1%)
  No 1 (3.3%) 15 (65.3%) 26 (74.3%)
  Unknown 26 (86.7%) 7 (30.4%) 3 (8.6%)
ER Yes 23 (76.7%) 20 (87.0%) 23 (65.7%)
  No 2 (6.7%) 2 (8.7%) 10 (28.6%)
  Unknown 5 (16.6%) 1 (4.3%) 2 (5.7%)
PR Yes 17 (56.7%) 19 (82.6%) 19 (54.3%)
  No 7 (23.3%) 3 (3.0%) 13 (37.1%)
  Unknown 6 (20.0%) 1 (4.4%) 3 (8.6%)